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Infants with acute myeloid leukemia treated
according to the Associazione Italiana di
Ematologia e Oncologia Pediatrica 2002/01 
protocol have an outcome comparable to that 
of older children
Children under the age of one year (i.e. infants) with
acute myeloid leukemia (AML) represent a distinct sub-
group of patients with peculiar clinical and biological char-
acteristics.1 As compared to older children, a higher preva-
lence of unfavorable clinical and cytogenetic/molecular
features has frequently been reported in this age group.1,2
While the outcome of infants with acute lymphoblastic
leukemia is still worse than that of older children,3 in
recent years, this may not be the case for infants with
AML. In particular, consistent with the significant progress
generally achieved in the outcome of childhood AML,1 the
event-free survival (EFS) of infants with AML has
increased from less than 35% in the past4 to more than
50% in recently published studies.5 It is unclear whether
and to what extent a wide use of allogeneic (ALLO)
hematopoietic stem cell transplantation (HSCT) in first
complete remission (CR), has contributed to the improved
outcome of these particular patients. In the AML 2002/01
study of the Associazione Italiana di Ematologia e
Oncologia Pediatrica (AIEOP)6, infants achieving CR1
were most often offered either allo-HSCT or, less frequent-
ly, autologous (auto)-HSCT as post-remission therapy.
Here we report clinical/biological characteristics, as well as
outcome, of infants, comparing the results with those of
older children treated in that protocol. We analyzed chil-
dren aged one year or under year at diagnosis, with de novo
non-promyelocytic AML, treated between December
2002 and June 2011 according to the AIEOP AML 2002/01
protocol; children with Down syndrome were not includ-
ed in this study as they were treated with a specific proto-
col (i.e. AIEOP AML 2002/02). Details on the diagnostic
workup, as well as on the cytogenetic/molecular character-
ization, have been reported elsewhere.6
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Table 1. Clinical, cytogenetic and biological features of infants enrolled in the AIEOP AML 2002/01 protocol compared with those of older
patients.
Age groups                                                                   Infants                1–<2 years 2–<10 years >10 years P
                                                                                     N (%)                       N (%) N (%) N (%)
Number of patients                                                                      63                                  52 181 186
Leukocytes (x109/L), median (min–max)                    71.2  (3.1-653)            46.9  (3.3-671) 45.9 (6.6-475) 39.7 (7-165)
Sex: male                                                                                 31/63 (49)                   24/52 (46) 103/181 (57) 104/186 (56) 0.434
CNS leukemia                                                                         10/63 (16)                    6/52 (12) 5/181 (3) 16/186 (9) 0.002
Extramedullary leukemia (Non-CNS)                               9/63 (15)                     6/52 (12) 30/181 (17) 32/186 (18) 0.809
Leukocytes  >100x109/L                                                        13/63 (21)                    9/52 (17) 25/181 (14) 30/186 (16) 0.598
FAB M0                                                                                      8/63 (13)                      4/52 (8) 9/181 (5) 13/186 (7) 0.231
FAB M1                                                                                      8/63 (13)                     5/52 (10) 31/181 (17) 44/186 (24) 0.042
FAB M2                                                                                       3/63 (5)                       1/52 (2) 45/181 (25) 42/186 (23) <0.001
FAB M4                                                                                     10/63 (16)                     4/52 (8) 34/181 (19) 35/186 (19) 0.103
FAB M5                                                                                     20/63 (32)                   17/52 (33) 40/181 (22) 40/186 (22) 0.133
FAB M6                                                                                       0/63 (0)                       1/52 (2) 2/181 (1) 2/186 (1) 0.568
FAB M7                                                                                     12/63 (19)                   17/52 (33) 13/181 (7) 2/186 (1) <0.001
Unclassifiable/not known                                                      2/63 (3)                       3/52 (6) 7/181 (4) 8/186 (4) 0.760
SR risk group                                                                            4/63 (6)                      5/52 (10) 43/181 (24) 47/186 (25) 0.001
HR risk group                                                                          59/63 (94)                   47/52 (90) 138/181 (76) 139/186 (75) 0.001
Patients with available cytogenetic data                          58/63 (92)                   46/52 (88) 156/181 (86) 158/186 (85) 0.553
Complex karyotype                                                                 6/58 (10)                      3/46 (7). 9/156 (7) 11/158 (7) 0.685
Favorable cytogenetic t(8;21).t(16;16) or inv(16)           4/63 (6)                      5/52 (10) 43/181 (24) 47/186 (25) 0.001
11q23/MLL-rearrangements                                                21/58 (36)                   13/46 (30) 25/156 (13) 22/158 (14) 0.001
t(9;11)(p22;q23) and/or MLL-AF9                                       6/58 (10)                      3/46 (7) 10/156 (6) 8/158 (5) 0.553
t(10;11)(p11.2;q23) and/or MLL-AF10                                 4/58 (7)                       2/46 (4) 6/156 (4) 5/158 (3) 0.613
t(11;19) (q23;p13)                                                                   1/58 (1)                       2/46 (4) 2/156 (1) 2/158 (1) 0.423
t(1;11) (variable;q23)                                                             2/58 (4)                       3/46 (7) 2/156 (1) 1/158 (1) 0.051
MLL rearrangement with other partners                         8/58 (14)                      3/46 (7) 5/156 (3) 6/158 (4) 0.023
t(1;22)(p13;q13)                                                                       3/58 (5)                       1/46 (2) 0/156 (0) 0/158 (0) 0.020
Patients tested for FLT3 aberrations                               50/63 (79)                   40/52 (77) 140/181 (77) 154/186 (83) 0.694
FLT3-ITD mutations                                                                 1/50(2)                        2/40 (5) 10/140 (7) 39/154 (25) <0.001
Patients tested for NPM and CEBP aberrations          28/63 (45)                   21/52 (40) 99/181 (55) 103/186 (55) 0.08
NPM mutations                                                                         1/28 (4)                       0/21 (0) 7/99 (7) 7/103 (8) 0.035
CEBP  mutations                                                                      1/28 (4)                       0/21 (0) 5/99 (5) 12/134 (9) 0.022
N: number of patients; CNS: central nervous system; SR: standard risk; HR: high risk.
Infants of the AIEOP AML 2002/01 study6 received two
courses of induction chemotherapy, including idarubicin,
Ara-C and etoposide (see Pession et al.6 for details).
Children achieving CR received two consolidation courses,
containing high-dose (HD) Ara-C, combined with either
etoposide or mitoxantrone in the first and second course,
respectively. The dosage of cytotoxic drugs was adapted
for infants according to the following formula: weight (kg)
x dose (x m2)/30, the only exception being represented by
the dose of HD-Ara-C, administered as 20%, 30%, 40%,
50% and 60% to infants aged under 3, 4-5, 6-7, 8-10 and
11-12 months, respectively, in view of the reduced Ara-C
clearance of these patients.7 At the end of consolidation,
infants carrying t(8:21), inv(16) or t(16;16) (standard risk
group) received a fifth course of HD Ara-C. The remaining
high-risk (HR) infants were offered allo-HSCT from either
matched family donors (MFD) or alternative donors. In 7
children lacking a matched related or matched unrelated
donor, the treating physician decided not to perform an
allograft, but opted for auto-HSCT. 
Infants’ clinical and biological features at presentation,
compared with those of other age groups, are detailed in
Table 1. Compared to older children, infants had signifi-
cantly more central nervous system involvement at diag-
nosis (P=0.002) (Table 1). French-American-British (FAB)
subtypes M1 (P=0.042) and M2 (P<0.001) were more com-
mon in older children, while infants presented more fre-
quently with a FAB-M5 (P=0.008) or M7 subtype
(P<0.001). In comparison to older children, infants were
allocated more frequently to the HR group (P=0.001) (see
Pession et al.6 for details).
Infants showed a significantly higher incidence (i.e.
36%) of 11q23/MLL rearrangements (P=0.001) than older
children. All cases with t(1;22)(p13;q13) but one were
infants belonging to the FAB-M7 subtype (Table 1). FLT-3
aberrations, namely internal tandem duplication and acti-
vating loop mutations, were present only in 2% and 5% of
patients aged under one year and those aged one to under
two years, respectively, while they were found in 7-25%
of older children (P=0.001). Notably, 6 (9.5%) out of the 63
infants harbored inv(16)(p13.3q24.3) encoding for the
cryptic fusion transcript CBFA2T3-GLIS2 that we identi-
fied through whole-transcriptome sequencing and con-
firmed using Sanger techniques; 4 of them had a FAB-M7
blast morphology.8 This cryptic translocation is much less
common than the classical inversion of chromosome 16
and can be detected only by specific molecular/cytogenetic
probes.8,9 
Results of the outcome of infants compared to those of
other age groups are reported in Table 2. CR, early death
and induction failure rates were 82%, 3% and 14%,
respectively, with no statistical difference to rates for older
patients. Only 3 infants died in CR: 2 during consolidation
due to Gram-negative sepsis and one after transplantation.
Compared to older children, severe mucositis occurred less
frequently in infants (25% vs. 35%, respectively) (P=0.04),
while the incidence of the remaining chemotherapy-relat-
ed toxicities was superimposable. The cumulative inci-
dence of relapse was 31%.
Four patients were not offered HSCT as they carried a
favorable cytogenetic profile. All these 4 children are alive
and disease free. 
Forty-six infants out of 63 received HSCT in CR1: 7 chil-
dren were given auto- and 39 allo-HSCT. With a median
follow up of 57 months (range 12-130 months), the 8-year
overall survival (OS) and EFS probabilities of the whole
population of infants were 74% (Standard Error (SE) 5.7)
and 55% (SE 6.4), respectively, showing no difference to
those of other age groups (Table 2). In multivariate analy-
sis, only blast count over 5% at time of hematologic recov-
ery after induction negatively affected prognosis (P=0.03).
Overall survival and EFS of infants undergoing HSCT in
CR1 was 72% (SE 6.8) and 58% (SE 7.1), respectively.
Neither type of donor nor stem cell source influenced the
probabilities of OS and EFS in allo-HSCT recipients (data
not shown). Notably, the small group of infants harboring
the CBFA2T3-GLIS2 fusion transcript had a significantly
worse prognosis (EFS 32.3%, SE 19.2) compared with
CBFA2T3-GLIS2 negative infants (59.6%, SE 6.6) (P<0.05).
Outcome of infants was not influenced be the presence of
11q23 MLL rearrangement (data not shown). Among trans-
planted infants, 14% experienced growth deficiency, 3%
decreased cardiac function, 9% hypothyroidism and 6%
have impaired cognitive function. 
Besides confirming and extending previously reported
observations, our data demonstrate for the first time that,
in infants, CBFA2T3-GLIS2 fusion transcript seems to be
as frequent as OTT-MAL fusion in FAB-M7 AML, this
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Table 2. Outcome results of infants enrolled in the AIEOP AML 2002/01 protocol compared with older patients.
Age groups Infants 1–<2 years  2–<10 years >10 years P
N (%) N (%) N (%) N (%)
Number of patients 63 52 181 186
CR achieved after induction 52/63 (82) 48/52 (92) 156/181 (86) 161/181 (88) 0.20
Non-responders 9/63 (14) 3/52 (6) 20/181 (11) 16/186 (9) 0.28
Early death 2/63 (3) 1/52 (2) 5/181 (3) 5/186 (3) 0.96
% (SE) % (SE) % (SE) %  (SE) P
OS at 8 years 73.7 (5.7) 66.4 (7.0) 62.8 (4.3) 65.4 (3.9) 0.81
EFS at 8 years 54.6 (6.1) 58.7 (7.2) 54.3 (4.6) 54.4 (4.0) 0.87
DFS at 8 years 64.9 (6.7) 62.1 (7.4) 62.1 (5.0) 62.4 (4.3) 0.87
CI of relapse at 8 years 31.3 (6.5) 25.7 (6.4) 30.5 (4.7) 22.9 (3.4) 0.61
CI of death in CR at 8 years 3.8 (1.0) 12.1 (5.2) 7.3 (2.5) 14.7 (3.3) 0.06
N: number of patients; SE: standard error; CR: complete remission; OS: overall survival; EFS: event-free survival; DFS: disease-free survival; CI: cumulative incidence.
lesion predicting a grim prognosis. Moreover, our results
suggest that a treatment strategy combining intensive
chemotherapy and a widespread use of HSCT in CR1 is
able to abolish the impact of unfavorable prognostic char-
acteristics of infants. The outcome of our patients is similar
to that reported by the I-BFM,2 MRC10 and Japanese
groups,5 in which, however, HSCT was not widely used.
In the new AIEOP-AML study, post-remission treatment
will be tailored to reduce the proportion of transplanted
infants with predicted disease recurrence, in view of the
more frequent and severe HCST-related long-term compli-
cations.11 
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